Retatrutide, a groundbreaking dual-acting glucose-regulated incretin mimetic, represents a significant advance in peptide medicines for the handling of type 2 sugar disorders and, increasingly, excess adiposity. Unlike many existing therapeutic interventions, retatrutide merges the actions of a GLP-1 receptor agonist and a GIP receptor agonist, off